Symbiotec Pharmalab Limited (SYMBIOTEC) fundamentals
Symbiotec Pharmalab Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SYMBIOTEC (ISIN INE899I01028). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
Valuation and market data
| Last close | ₹1229.80 |
|---|---|
| Market capitalisation | ₹7,076 crore |
| Enterprise value | ₹7,170 crore |
| P/E (TTM) | 11.43 |
| Price to book | 6.16 |
| Price to sales (TTM) | 3.46 |
| Book value per share | ₹199.79 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Tue Sep 01 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹902 crore | ₹173 crore | ₹116 crore | 0.00 |
| Mar 2025 | ₹789 crore | ₹196 crore | ₹146 crore | 133.35 |
| Mar 2024 | ₹693 crore | ₹118 crore | ₹89 crore | 81.33 |
| Mar 2023 | ₹576 crore | ₹-8 crore | ₹-23 crore | -20.72 |
| Mar 2022 | ₹640 crore | ₹83 crore | ₹62 crore | 56.45 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 33.3% |
|---|---|
| Foreign institutions (FII) | 3.8% |
| Mutual funds | 12.2% |
| Other domestic institutions | 21.0% |
| Retail and others | 29.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.